Skip to main content

Respiratory

13 drugs are in development for COVID-19.

Companies
9
Clinical trials
85
BioSniper AIPage evidence connected

Prepared research question

Which programs lead the COVID-19 pipeline—and what evidence could change the picture?

Run cited research

Traceable citations · Unknowns marked

Drug Pipeline by Phase

Phase 3(2)
DrugCompany
cicNOVAVAX INC (NVAX)
vyd2311Invivyd, Inc. (IVVD)
Phase 1(1)
DrugCompany
ocu500Ocugen, Inc. (OCGN)
Preclinical(2)
DrugCompany
nv-cov-2NANOVIRICIDES, INC. (NNVC)
nv-cov-2-rNANOVIRICIDES, INC. (NNVC)
Phase 1/Phase 2(1)
DrugCompany
vbi-2901VBI VACCINES INC/BC (VBIV)
About this indication

COVID-19 context

Respiratory·MeSH: COVID-19 (D000086382)

Also known as: 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019 nCoV Disease, 2019 nCoV Infection, 2019-nCoV Diseases, 2019-nCoV Infections, COVID 19 Virus Disease, COVID 19 Virus Infection, COVID-19 Virus Diseases, COVID-19 Virus Infections, COVID19, Coronavirus Disease 19, Disease 2019, Coronavirus, Infection, SARS-CoV-2, SARS Coronavirus 2 Infection, SARS-CoV-2 Infections, Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Prevalence

10000.0 / 100K

Incidence

5000.0 / 100K/yr

Frequently asked questions

How many drugs are in development for COVID-19?

BioSniper tracks 13 drugs in development for COVID-19 across 9 companies.

How many clinical trials target COVID-19?

There are 85 clinical trials targeting COVID-19 tracked by BioSniper.

What is the prevalence of COVID-19?

The estimated prevalence of COVID-19 is approximately 10000.0 per 100,000 population.